Literature DB >> 35393140

Letter to Editor: Association of body mass index with COVID-19 related in-hospital death.

Serdar Ceylan1, Cafer Balcı2.   

Abstract

Entities:  

Keywords:  Body mass index; COVID-19; Mortality; Obesity; Sarcopenia

Year:  2022        PMID: 35393140      PMCID: PMC8902860          DOI: 10.1016/j.clnu.2022.03.009

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


× No keyword cloud information.
Dear Editor, We carefully read the article by Bouziotis and colleagues describing the importance of body mass index (BMI) in Coronavirus Disease 2019 (COVID-19)-related hospital deaths with great interest [1]. According to the results of the study, being obese, overweight, and normal-weight were associated with decreased risk of in-hospital mortality when compared to being underweight. While there are numerous studies in the literature examining the relationship between BMI and the risk of death in hospitalized COVID-19 patients, this study emphasized the protective effect of being overweight, unlike previous information [2]. However, there may be some residual confounding factors when interpreting the results of the study. Even though the mean age of the participants of the study was 60 ± 16.2 years, the authors didn't provide the details of the proportions of the patients aged 65 years and older in each BMI group. Two consequences of this situation should be considered when evaluating the study. First, the most common group that died due to COVID-19 is the advanced age group [3]. Second, in Europe, which provided the highest patient contribution to the present study, the ratio of death due to COVID-19 in older adults (≥70 years) is 86.6% [3]. Considering that the mean age of the study was 60 years and the primary outcome was death, underrepresentation of the geriatric age group may have affected the results. Another important issue is the possible coexistence of sarcopenia and obesity. Sarcopenic overweight and sarcopenic obesity (SO), which are important subheadings of sarcopenia, can be seen in all age groups, especially in older adults [4]. It is stated that SO could be associated with the severity of the disease and death in COVID-19 patients [5]. Muscle mass and muscle strength, which are the components of sarcopenia, should be used together with BMI, and it should be taken into account when evaluating the results of the study. In brief, this impressive report provides the data showing the role of BMI in assessing the risk of death in hospitalized COVID-19 patients. With the clarification of the specified points, the results of the study will be interpreted more accurately.

Author contribution

Serdar CEYLAN: Methodology, Writing, Original Draft Preparation, Review. Cafer BALCI: Conceptualization, Methodology, Writing, Original Draft Preparation, Review & Editing, Supervision.

Funding statement

None.

Conflict of interest

The authors declare that they have no conflict of interest.
  5 in total

1.  Sarcopenic obesity and the risk of hospitalization or death from coronavirus disease 2019: findings from UK Biobank.

Authors:  Thomas J Wilkinson; Thomas Yates; Luke A Baker; Francesco Zaccardi; Alice C Smith
Journal:  JCSM Rapid Commun       Date:  2021-07-03

2.  Prevalence of sarcopenic obesity and sarcopenic overweight in the general population: The lifelines cohort study.

Authors:  Carlijn A Wagenaar; Louise H Dekker; Gerjan J Navis
Journal:  Clin Nutr       Date:  2021-01-11       Impact factor: 7.324

3.  Association of Body mass index (BMI) with Critical COVID-19 and in-hospital Mortality: a dose-response meta-analysis.

Authors:  Yanbin Du; Yuan Lv; Wenting Zha; Nan Zhou; Xiuqin Hong
Journal:  Metabolism       Date:  2020-09-16       Impact factor: 8.694

4.  Association of body mass index with COVID-19 related in-hospital death.

Authors:  Jason Bouziotis; Marianna Arvanitakis; Jean-Charles Preiser
Journal:  Clin Nutr       Date:  2022-01-29       Impact factor: 7.324

5.  Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis.

Authors:  Changcheng Shi; Limin Wang; Jian Ye; Zhichun Gu; Shuying Wang; Junbo Xia; Yaping Xie; Qingyu Li; Renjie Xu; Nengming Lin
Journal:  BMC Infect Dis       Date:  2021-07-08       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.